logo
Products
Services
Resources
Selection Guides
About
PerCP/Cy5.5 Anti-human CD3 Antibody
HIT3a
HIT3a is an anti-human monoclonal antibody that recognizes the CD3e antigen. CD3e (sometimes referred to as T cell antigen receptor complex or T3E) is a 20 kD member of the Ig superfamily that is found on the surface of cells like T cells. CD3 acts in essential cellular pathways, namely, the G protein-coupled receptor signaling pathway, apoptotic signaling pathway and T cell receptor signaling pathway. In addition, in certain organisms, it positively regulates T cell anergy, acts to positively regulate cell-matrix adhesion and is involved in the positive regulation of calcium-mediated signaling. From a research standpoint, it is of biological interest due to its association with essential macromolecules/ligands such as TCR. CD3 is a very popular antibody target, with over 80000 publications in the last decade. CD3e is typically used in flow cytometry applications as a phenotypic marker for differentiation of cell types, especially in the study of immunology. This antibody was purified through affinity chromatography and conjugated to PerCP/Cy5.5 (ex/em = 489/679 nm). It is compatible with the 488 nm laser and 693/37 nm bandpass filter (for example, as in the Miltenyi Biotec MACSQuant Analyzer 10).
product image
product image
CatalogSize
Price
Quantity
100301U025 tests
Price
100301U1100 tests
Price
100301U2500 tests
Price
 
Antibody properties

Other namesT3E
CloneHIT3a
HostMouse
IsotypeIgG2a
ReactivityHuman
Spectral properties

Extinction coefficient (cm -1 M -1)
350000
Excitation (nm)482
Emission (nm)695
Storage, safety and handling

H-phraseH303, H313, H333
Hazard symbolXN
Intended useResearch Use Only (RUO)
R-phraseR20, R21, R22
Contact us

Telephone
Fax
Emailsales@aatbio.com
InternationalSee distributors
Bulk requestInquire
Custom sizeInquire
Technical SupportContact us
Request quotationRequest
Purchase orderSend to sales@aatbio.com
ShippingStandard overnight for United States, inquire for international
Page updated on April 1, 2026